Evidence map›Paper›PMID 42452962›Full record

ReviewACS chemical neuroscience2026

Serotonergic System Dysregulation in Alzheimer's Disease.

Nour F Al-Ghraiybah, Amer E Alkhalifa, Dylan Spivey, Thomas Averill, Blake Engelkemier, Patricia Haro Lopez, Mary Grace Stuckey, Luke Jenkins, Amal Kaddoumi

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in ACS chemical neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Nour F Al-GhraiybahDepartment of Pharmacology and Toxicology, Medical College of Georgia, Augusta University, Augusta, Georgia30912, United States.
Amer E AlkhalifaDepartment of Pharmacology and Toxicology, Medical College of Georgia, Augusta University, Augusta, Georgia30912, United States.
Dylan SpiveyDepartment of Drug Discovery and Development, Harrison College of Pharmacy, Auburn University, Auburn, Alabama36849, United States.
Thomas AverillDepartment of Drug Discovery and Development, Harrison College of Pharmacy, Auburn University, Auburn, Alabama36849, United States.ORCID 0009-0009-7550-7176
Blake EngelkemierDepartment of Drug Discovery and Development, Harrison College of Pharmacy, Auburn University, Auburn, Alabama36849, United States.
Patricia Haro LopezDepartment of Pharmacology and Toxicology, Medical College of Georgia, Augusta University, Augusta, Georgia30912, United States.
Mary Grace StuckeyDepartment of Drug Discovery and Development, Harrison College of Pharmacy, Auburn University, Auburn, Alabama36849, United States.
Luke JenkinsDepartment of Drug Discovery and Development, Harrison College of Pharmacy, Auburn University, Auburn, Alabama36849, United States.
Amal KaddoumiDepartment of Pharmacology and Toxicology, Medical College of Georgia, Augusta University, Augusta, Georgia30912, United States.ORCID 0000-0001-9792-7766

Funding

5HT3 receptors and blood-brain barrier dysfunction in ADRDR21NS130503 · NINDS · AUGUSTA UNIVERSITY · PI KHALIL KADDOUMI, AMAL F · 2023 to 2023
$392k
NINDS NIH HHS R21 NS130503NINDS NIH HHS R21NS130503
6 · The paper itself

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by several key hallmarks, including the accumulation of amyloid-β (Aβ), neurofibrillary tangles (NFTs), neuroinflammation, and blood-brain barrier (BBB) dysfunction. Similar to other neurodegenerative diseases, AD involves disturbances in neurotransmitter homeostasis. However, the serotonergic system is complex, involving numerous mechanisms and pathways, which complicates the establishment of direct correlations with AD. This review examines the serotonergic system, focusing on alterations in serotonin (5-HT), its transporter, and its receptors in the context of AD, to identify current knowledge gaps and highlight ongoing research directions. It also emphasizes the role of 5-HT in vascular regulation and BBB integrity, and links the gut-brain axis to the serotonergic system.

Indexed as

Alzheimer DiseaseBrainSerotoninAnimalsBlood-Brain BarrierHumansReceptors, SerotoninReceptors, SerotoninSerotoninAlzheimer’s diseaseblood–brain barriergut-brain axisneurodegenerative disordersneurotransmittersserotonergic systemserotonin

Identifiers

PMID42452962
PMCPMC13449768

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.